The global market for Posterior Segment Eye Disorder Treatment was valued at US$ 32290 million in the year 2024 and is projected to reach a revised size of US$ 46730 million by 2031, growing at a CAGR of 5.5% during the forecast period.

Posterior Segment Eye Disorder Treatment Market

Posterior segment eye disorders affect the back part of the eye, which includes the retina, choroid, and optic nerve. These disorders can cause a variety of vision problems, including blurred vision, floaters, and vision loss.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Posterior Segment Eye Disorder Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Posterior Segment Eye Disorder Treatment.

The Posterior Segment Eye Disorder Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Posterior Segment Eye Disorder Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Posterior Segment Eye Disorder Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Posterior Segment Eye Disorder Treatment Market Report

Report Metric	Details
Report Name	Posterior Segment Eye Disorder Treatment Market
Accounted market size in year	US$ 32290 million
Forecasted market size in 2031	US$ 46730 million
CAGR	5.5%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Glaucoma Treatment Age-related Macular Degeneration (AMD) Treatment Diabetic Retinopathy (DR) Treatment
Segment by Application	Hospital Clinic Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Novartis, Allergan, Pfizer, Akorn, Teva, Bausch & Lomb, Otsuka Pharmaceutical, Santen, Lunan Pharma, Zizhu Pharma, Bayer, Roche, Alimera Sciences, Regeneron Pharmaceuticals, Boehringer Ingelheim, Kowa Group, Ohr Pharmaceutical, Quark Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Posterior Segment Eye Disorder Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Posterior Segment Eye Disorder Treatment Market growing?

Ans: The Posterior Segment Eye Disorder Treatment Market witnessing a CAGR of 5.5% during the forecast period 2025-2031.

What is the Posterior Segment Eye Disorder Treatment Market size in 2031?

Ans: The Posterior Segment Eye Disorder Treatment Market size in 2031 will be US$ 46730 million.

Who are the main players in the Posterior Segment Eye Disorder Treatment Market report?

Ans: The main players in the Posterior Segment Eye Disorder Treatment Market are Novartis, Allergan, Pfizer, Akorn, Teva, Bausch & Lomb, Otsuka Pharmaceutical, Santen, Lunan Pharma, Zizhu Pharma, Bayer, Roche, Alimera Sciences, Regeneron Pharmaceuticals, Boehringer Ingelheim, Kowa Group, Ohr Pharmaceutical, Quark Pharmaceuticals

What are the Application segmentation covered in the Posterior Segment Eye Disorder Treatment Market report?

Ans: The Applications covered in the Posterior Segment Eye Disorder Treatment Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Posterior Segment Eye Disorder Treatment Market report?

Ans: The Types covered in the Posterior Segment Eye Disorder Treatment Market report are Glaucoma Treatment, Age-related Macular Degeneration (AMD) Treatment, Diabetic Retinopathy (DR) Treatment

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Posterior Segment Eye Disorder Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Glaucoma Treatment

1.2.3 Age-related Macular Degeneration (AMD) Treatment

1.2.4 Diabetic Retinopathy (DR) Treatment

1.3 Market by Application

1.3.1 Global Posterior Segment Eye Disorder Treatment Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Posterior Segment Eye Disorder Treatment Market Perspective (2020-2031)

2.2 Global Posterior Segment Eye Disorder Treatment Growth Trends by Region

2.2.1 Global Posterior Segment Eye Disorder Treatment Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Posterior Segment Eye Disorder Treatment Historic Market Size by Region (2020-2025)

2.2.3 Posterior Segment Eye Disorder Treatment Forecasted Market Size by Region (2026-2031)

2.3 Posterior Segment Eye Disorder Treatment Market Dynamics

2.3.1 Posterior Segment Eye Disorder Treatment Industry Trends

2.3.2 Posterior Segment Eye Disorder Treatment Market Drivers

2.3.3 Posterior Segment Eye Disorder Treatment Market Challenges

2.3.4 Posterior Segment Eye Disorder Treatment Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Posterior Segment Eye Disorder Treatment Players by Revenue

3.1.1 Global Top Posterior Segment Eye Disorder Treatment Players by Revenue (2020-2025)

3.1.2 Global Posterior Segment Eye Disorder Treatment Revenue Market Share by Players (2020-2025)

3.2 Global Posterior Segment Eye Disorder Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Posterior Segment Eye Disorder Treatment Revenue

3.4 Global Posterior Segment Eye Disorder Treatment Market Concentration Ratio

3.4.1 Global Posterior Segment Eye Disorder Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Posterior Segment Eye Disorder Treatment Revenue in 2024

3.5 Global Key Players of Posterior Segment Eye Disorder Treatment Head office and Area Served

3.6 Global Key Players of Posterior Segment Eye Disorder Treatment, Product and Application

3.7 Global Key Players of Posterior Segment Eye Disorder Treatment, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Posterior Segment Eye Disorder Treatment Breakdown Data by Type

4.1 Global Posterior Segment Eye Disorder Treatment Historic Market Size by Type (2020-2025)

4.2 Global Posterior Segment Eye Disorder Treatment Forecasted Market Size by Type (2026-2031)

5 Posterior Segment Eye Disorder Treatment Breakdown Data by Application

5.1 Global Posterior Segment Eye Disorder Treatment Historic Market Size by Application (2020-2025)

5.2 Global Posterior Segment Eye Disorder Treatment Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Posterior Segment Eye Disorder Treatment Market Size (2020-2031)

6.2 North America Posterior Segment Eye Disorder Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Posterior Segment Eye Disorder Treatment Market Size by Country (2020-2025)

6.4 North America Posterior Segment Eye Disorder Treatment Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Posterior Segment Eye Disorder Treatment Market Size (2020-2031)

7.2 Europe Posterior Segment Eye Disorder Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Posterior Segment Eye Disorder Treatment Market Size by Country (2020-2025)

7.4 Europe Posterior Segment Eye Disorder Treatment Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Posterior Segment Eye Disorder Treatment Market Size (2020-2031)

8.2 Asia-Pacific Posterior Segment Eye Disorder Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Posterior Segment Eye Disorder Treatment Market Size by Region (2020-2025)

8.4 Asia-Pacific Posterior Segment Eye Disorder Treatment Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Posterior Segment Eye Disorder Treatment Market Size (2020-2031)

9.2 Latin America Posterior Segment Eye Disorder Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Posterior Segment Eye Disorder Treatment Market Size by Country (2020-2025)

9.4 Latin America Posterior Segment Eye Disorder Treatment Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Posterior Segment Eye Disorder Treatment Market Size (2020-2031)

10.2 Middle East & Africa Posterior Segment Eye Disorder Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Posterior Segment Eye Disorder Treatment Market Size by Country (2020-2025)

10.4 Middle East & Africa Posterior Segment Eye Disorder Treatment Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Novartis

11.1.1 Novartis Company Details

11.1.2 Novartis Business Overview

11.1.3 Novartis Posterior Segment Eye Disorder Treatment Introduction

11.1.4 Novartis Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025)

11.1.5 Novartis Recent Development

11.2 Allergan

11.2.1 Allergan Company Details

11.2.2 Allergan Business Overview

11.2.3 Allergan Posterior Segment Eye Disorder Treatment Introduction

11.2.4 Allergan Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025)

11.2.5 Allergan Recent Development

11.3 Pfizer

11.3.1 Pfizer Company Details

11.3.2 Pfizer Business Overview

11.3.3 Pfizer Posterior Segment Eye Disorder Treatment Introduction

11.3.4 Pfizer Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025)

11.3.5 Pfizer Recent Development

11.4 Akorn

11.4.1 Akorn Company Details

11.4.2 Akorn Business Overview

11.4.3 Akorn Posterior Segment Eye Disorder Treatment Introduction

11.4.4 Akorn Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025)

11.4.5 Akorn Recent Development

11.5 Teva

11.5.1 Teva Company Details

11.5.2 Teva Business Overview

11.5.3 Teva Posterior Segment Eye Disorder Treatment Introduction

11.5.4 Teva Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025)

11.5.5 Teva Recent Development

11.6 Bausch & Lomb

11.6.1 Bausch & Lomb Company Details

11.6.2 Bausch & Lomb Business Overview

11.6.3 Bausch & Lomb Posterior Segment Eye Disorder Treatment Introduction

11.6.4 Bausch & Lomb Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025)

11.6.5 Bausch & Lomb Recent Development

11.7 Otsuka Pharmaceutical

11.7.1 Otsuka Pharmaceutical Company Details

11.7.2 Otsuka Pharmaceutical Business Overview

11.7.3 Otsuka Pharmaceutical Posterior Segment Eye Disorder Treatment Introduction

11.7.4 Otsuka Pharmaceutical Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025)

11.7.5 Otsuka Pharmaceutical Recent Development

11.8 Santen

11.8.1 Santen Company Details

11.8.2 Santen Business Overview

11.8.3 Santen Posterior Segment Eye Disorder Treatment Introduction

11.8.4 Santen Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025)

11.8.5 Santen Recent Development

11.9 Lunan Pharma

11.9.1 Lunan Pharma Company Details

11.9.2 Lunan Pharma Business Overview

11.9.3 Lunan Pharma Posterior Segment Eye Disorder Treatment Introduction

11.9.4 Lunan Pharma Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025)

11.9.5 Lunan Pharma Recent Development

11.10 Zizhu Pharma

11.10.1 Zizhu Pharma Company Details

11.10.2 Zizhu Pharma Business Overview

11.10.3 Zizhu Pharma Posterior Segment Eye Disorder Treatment Introduction

11.10.4 Zizhu Pharma Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025)

11.10.5 Zizhu Pharma Recent Development

11.11 Bayer

11.11.1 Bayer Company Details

11.11.2 Bayer Business Overview

11.11.3 Bayer Posterior Segment Eye Disorder Treatment Introduction

11.11.4 Bayer Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025)

11.11.5 Bayer Recent Development

11.12 Roche

11.12.1 Roche Company Details

11.12.2 Roche Business Overview

11.12.3 Roche Posterior Segment Eye Disorder Treatment Introduction

11.12.4 Roche Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025)

11.12.5 Roche Recent Development

11.13 Alimera Sciences

11.13.1 Alimera Sciences Company Details

11.13.2 Alimera Sciences Business Overview

11.13.3 Alimera Sciences Posterior Segment Eye Disorder Treatment Introduction

11.13.4 Alimera Sciences Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025)

11.13.5 Alimera Sciences Recent Development

11.14 Regeneron Pharmaceuticals

11.14.1 Regeneron Pharmaceuticals Company Details

11.14.2 Regeneron Pharmaceuticals Business Overview

11.14.3 Regeneron Pharmaceuticals Posterior Segment Eye Disorder Treatment Introduction

11.14.4 Regeneron Pharmaceuticals Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025)

11.14.5 Regeneron Pharmaceuticals Recent Development

11.15 Boehringer Ingelheim

11.15.1 Boehringer Ingelheim Company Details

11.15.2 Boehringer Ingelheim Business Overview

11.15.3 Boehringer Ingelheim Posterior Segment Eye Disorder Treatment Introduction

11.15.4 Boehringer Ingelheim Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025)

11.15.5 Boehringer Ingelheim Recent Development

11.16 Kowa Group

11.16.1 Kowa Group Company Details

11.16.2 Kowa Group Business Overview

11.16.3 Kowa Group Posterior Segment Eye Disorder Treatment Introduction

11.16.4 Kowa Group Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025)

11.16.5 Kowa Group Recent Development

11.17 Ohr Pharmaceutical

11.17.1 Ohr Pharmaceutical Company Details

11.17.2 Ohr Pharmaceutical Business Overview

11.17.3 Ohr Pharmaceutical Posterior Segment Eye Disorder Treatment Introduction

11.17.4 Ohr Pharmaceutical Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025)

11.17.5 Ohr Pharmaceutical Recent Development

11.18 Quark Pharmaceuticals

11.18.1 Quark Pharmaceuticals Company Details

11.18.2 Quark Pharmaceuticals Business Overview

11.18.3 Quark Pharmaceuticals Posterior Segment Eye Disorder Treatment Introduction

11.18.4 Quark Pharmaceuticals Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025)

11.18.5 Quark Pharmaceuticals Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Otsuka Pharmaceutical

Regeneron Pharmaceuticals

Boehringer Ingelheim

Kowa Group

Ohr Pharmaceutical

Quark Pharmaceuticals

List of Tables

Table 1. Global Posterior Segment Eye Disorder Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Glaucoma Treatment

Table 3. Key Players of Age-related Macular Degeneration (AMD) Treatment

Table 4. Key Players of Diabetic Retinopathy (DR) Treatment

Table 5. Global Posterior Segment Eye Disorder Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Posterior Segment Eye Disorder Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Posterior Segment Eye Disorder Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 8. Global Posterior Segment Eye Disorder Treatment Market Share by Region (2020-2025)

Table 9. Global Posterior Segment Eye Disorder Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 10. Global Posterior Segment Eye Disorder Treatment Market Share by Region (2026-2031)

Table 11. Posterior Segment Eye Disorder Treatment Market Trends

Table 12. Posterior Segment Eye Disorder Treatment Market Drivers

Table 13. Posterior Segment Eye Disorder Treatment Market Challenges

Table 14. Posterior Segment Eye Disorder Treatment Market Restraints

Table 15. Global Posterior Segment Eye Disorder Treatment Revenue by Players (2020-2025) & (US$ Million)

Table 16. Global Posterior Segment Eye Disorder Treatment Market Share by Players (2020-2025)

Table 17. Global Top Posterior Segment Eye Disorder Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Posterior Segment Eye Disorder Treatment as of 2024)

Table 18. Ranking of Global Top Posterior Segment Eye Disorder Treatment Companies by Revenue (US$ Million) in 2024

Table 19. Global 5 Largest Players Market Share by Posterior Segment Eye Disorder Treatment Revenue (CR5 and HHI) & (2020-2025)

Table 20. Global Key Players of Posterior Segment Eye Disorder Treatment, Headquarters and Area Served

Table 21. Global Key Players of Posterior Segment Eye Disorder Treatment, Product and Application

Table 22. Global Key Players of Posterior Segment Eye Disorder Treatment, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Posterior Segment Eye Disorder Treatment Market Size by Type (2020-2025) & (US$ Million)

Table 25. Global Posterior Segment Eye Disorder Treatment Revenue Market Share by Type (2020-2025)

Table 26. Global Posterior Segment Eye Disorder Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 27. Global Posterior Segment Eye Disorder Treatment Revenue Market Share by Type (2026-2031)

Table 28. Global Posterior Segment Eye Disorder Treatment Market Size by Application (2020-2025) & (US$ Million)

Table 29. Global Posterior Segment Eye Disorder Treatment Revenue Market Share by Application (2020-2025)

Table 30. Global Posterior Segment Eye Disorder Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 31. Global Posterior Segment Eye Disorder Treatment Revenue Market Share by Application (2026-2031)

Table 32. North America Posterior Segment Eye Disorder Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 33. North America Posterior Segment Eye Disorder Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 34. North America Posterior Segment Eye Disorder Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 35. Europe Posterior Segment Eye Disorder Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. Europe Posterior Segment Eye Disorder Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 37. Europe Posterior Segment Eye Disorder Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 38. Asia-Pacific Posterior Segment Eye Disorder Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 39. Asia-Pacific Posterior Segment Eye Disorder Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 40. Asia-Pacific Posterior Segment Eye Disorder Treatment Market Size by Region (2026-2031) & (US$ Million)

Table 41. Latin America Posterior Segment Eye Disorder Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 42. Latin America Posterior Segment Eye Disorder Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 43. Latin America Posterior Segment Eye Disorder Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 44. Middle East & Africa Posterior Segment Eye Disorder Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Middle East & Africa Posterior Segment Eye Disorder Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 46. Middle East & Africa Posterior Segment Eye Disorder Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 47. Novartis Company Details

Table 48. Novartis Business Overview

Table 49. Novartis Posterior Segment Eye Disorder Treatment Product

Table 50. Novartis Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025) & (US$ Million)

Table 51. Novartis Recent Development

Table 52. Allergan Company Details

Table 53. Allergan Business Overview

Table 54. Allergan Posterior Segment Eye Disorder Treatment Product

Table 55. Allergan Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025) & (US$ Million)

Table 56. Allergan Recent Development

Table 57. Pfizer Company Details

Table 58. Pfizer Business Overview

Table 59. Pfizer Posterior Segment Eye Disorder Treatment Product

Table 60. Pfizer Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025) & (US$ Million)

Table 61. Pfizer Recent Development

Table 62. Akorn Company Details

Table 63. Akorn Business Overview

Table 64. Akorn Posterior Segment Eye Disorder Treatment Product

Table 65. Akorn Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025) & (US$ Million)

Table 66. Akorn Recent Development

Table 67. Teva Company Details

Table 68. Teva Business Overview

Table 69. Teva Posterior Segment Eye Disorder Treatment Product

Table 70. Teva Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025) & (US$ Million)

Table 71. Teva Recent Development

Table 72. Bausch & Lomb Company Details

Table 73. Bausch & Lomb Business Overview

Table 74. Bausch & Lomb Posterior Segment Eye Disorder Treatment Product

Table 75. Bausch & Lomb Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025) & (US$ Million)

Table 76. Bausch & Lomb Recent Development

Table 77. Otsuka Pharmaceutical Company Details

Table 78. Otsuka Pharmaceutical Business Overview

Table 79. Otsuka Pharmaceutical Posterior Segment Eye Disorder Treatment Product

Table 80. Otsuka Pharmaceutical Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025) & (US$ Million)

Table 81. Otsuka Pharmaceutical Recent Development

Table 82. Santen Company Details

Table 83. Santen Business Overview

Table 84. Santen Posterior Segment Eye Disorder Treatment Product

Table 85. Santen Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025) & (US$ Million)

Table 86. Santen Recent Development

Table 87. Lunan Pharma Company Details

Table 88. Lunan Pharma Business Overview

Table 89. Lunan Pharma Posterior Segment Eye Disorder Treatment Product

Table 90. Lunan Pharma Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025) & (US$ Million)

Table 91. Lunan Pharma Recent Development

Table 92. Zizhu Pharma Company Details

Table 93. Zizhu Pharma Business Overview

Table 94. Zizhu Pharma Posterior Segment Eye Disorder Treatment Product

Table 95. Zizhu Pharma Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025) & (US$ Million)

Table 96. Zizhu Pharma Recent Development

Table 97. Bayer Company Details

Table 98. Bayer Business Overview

Table 99. Bayer Posterior Segment Eye Disorder Treatment Product

Table 100. Bayer Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025) & (US$ Million)

Table 101. Bayer Recent Development

Table 102. Roche Company Details

Table 103. Roche Business Overview

Table 104. Roche Posterior Segment Eye Disorder Treatment Product

Table 105. Roche Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025) & (US$ Million)

Table 106. Roche Recent Development

Table 107. Alimera Sciences Company Details

Table 108. Alimera Sciences Business Overview

Table 109. Alimera Sciences Posterior Segment Eye Disorder Treatment Product

Table 110. Alimera Sciences Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025) & (US$ Million)

Table 111. Alimera Sciences Recent Development

Table 112. Regeneron Pharmaceuticals Company Details

Table 113. Regeneron Pharmaceuticals Business Overview

Table 114. Regeneron Pharmaceuticals Posterior Segment Eye Disorder Treatment Product

Table 115. Regeneron Pharmaceuticals Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025) & (US$ Million)

Table 116. Regeneron Pharmaceuticals Recent Development

Table 117. Boehringer Ingelheim Company Details

Table 118. Boehringer Ingelheim Business Overview

Table 119. Boehringer Ingelheim Posterior Segment Eye Disorder Treatment Product

Table 120. Boehringer Ingelheim Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025) & (US$ Million)

Table 121. Boehringer Ingelheim Recent Development

Table 122. Kowa Group Company Details

Table 123. Kowa Group Business Overview

Table 124. Kowa Group Posterior Segment Eye Disorder Treatment Product

Table 125. Kowa Group Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025) & (US$ Million)

Table 126. Kowa Group Recent Development

Table 127. Ohr Pharmaceutical Company Details

Table 128. Ohr Pharmaceutical Business Overview

Table 129. Ohr Pharmaceutical Posterior Segment Eye Disorder Treatment Product

Table 130. Ohr Pharmaceutical Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025) & (US$ Million)

Table 131. Ohr Pharmaceutical Recent Development

Table 132. Quark Pharmaceuticals Company Details

Table 133. Quark Pharmaceuticals Business Overview

Table 134. Quark Pharmaceuticals Posterior Segment Eye Disorder Treatment Product

Table 135. Quark Pharmaceuticals Revenue in Posterior Segment Eye Disorder Treatment Business (2020-2025) & (US$ Million)

Table 136. Quark Pharmaceuticals Recent Development

Table 137. Research Programs/Design for This Report

Table 138. Key Data Information from Secondary Sources

Table 139. Key Data Information from Primary Sources

Table 140. Authors List of This Report

List of Figures

Figure 1. Posterior Segment Eye Disorder Treatment Picture

Figure 2. Global Posterior Segment Eye Disorder Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Posterior Segment Eye Disorder Treatment Market Share by Type: 2024 VS 2031

Figure 4. Glaucoma Treatment Features

Figure 5. Age-related Macular Degeneration (AMD) Treatment Features

Figure 6. Diabetic Retinopathy (DR) Treatment Features

Figure 7. Global Posterior Segment Eye Disorder Treatment Market Size by Application (2020-2031) & (US$ Million)

Figure 8. Global Posterior Segment Eye Disorder Treatment Market Share by Application: 2024 VS 2031

Figure 9. Hospital Case Studies

Figure 10. Clinic Case Studies

Figure 11. Others Case Studies

Figure 12. Posterior Segment Eye Disorder Treatment Report Years Considered

Figure 13. Global Posterior Segment Eye Disorder Treatment Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 14. Global Posterior Segment Eye Disorder Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global Posterior Segment Eye Disorder Treatment Market Share by Region: 2024 VS 2031

Figure 16. Global Posterior Segment Eye Disorder Treatment Market Share by Players in 2024

Figure 17. Global Top Posterior Segment Eye Disorder Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Posterior Segment Eye Disorder Treatment as of 2024)

Figure 18. The Top 10 and 5 Players Market Share by Posterior Segment Eye Disorder Treatment Revenue in 2024

Figure 19. North America Posterior Segment Eye Disorder Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. North America Posterior Segment Eye Disorder Treatment Market Share by Country (2020-2031)

Figure 21. United States Posterior Segment Eye Disorder Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Canada Posterior Segment Eye Disorder Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Posterior Segment Eye Disorder Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Posterior Segment Eye Disorder Treatment Market Share by Country (2020-2031)

Figure 25. Germany Posterior Segment Eye Disorder Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. France Posterior Segment Eye Disorder Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. U.K. Posterior Segment Eye Disorder Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Italy Posterior Segment Eye Disorder Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Russia Posterior Segment Eye Disorder Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Nordic Countries Posterior Segment Eye Disorder Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Posterior Segment Eye Disorder Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Posterior Segment Eye Disorder Treatment Market Share by Region (2020-2031)

Figure 33. China Posterior Segment Eye Disorder Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Japan Posterior Segment Eye Disorder Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. South Korea Posterior Segment Eye Disorder Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Southeast Asia Posterior Segment Eye Disorder Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. India Posterior Segment Eye Disorder Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Australia Posterior Segment Eye Disorder Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Posterior Segment Eye Disorder Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Posterior Segment Eye Disorder Treatment Market Share by Country (2020-2031)

Figure 41. Mexico Posterior Segment Eye Disorder Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Brazil Posterior Segment Eye Disorder Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Posterior Segment Eye Disorder Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Posterior Segment Eye Disorder Treatment Market Share by Country (2020-2031)

Figure 45. Turkey Posterior Segment Eye Disorder Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Saudi Arabia Posterior Segment Eye Disorder Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. UAE Posterior Segment Eye Disorder Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Novartis Revenue Growth Rate in Posterior Segment Eye Disorder Treatment Business (2020-2025)

Figure 49. Allergan Revenue Growth Rate in Posterior Segment Eye Disorder Treatment Business (2020-2025)

Figure 50. Pfizer Revenue Growth Rate in Posterior Segment Eye Disorder Treatment Business (2020-2025)

Figure 51. Akorn Revenue Growth Rate in Posterior Segment Eye Disorder Treatment Business (2020-2025)

Figure 52. Teva Revenue Growth Rate in Posterior Segment Eye Disorder Treatment Business (2020-2025)

Figure 53. Bausch & Lomb Revenue Growth Rate in Posterior Segment Eye Disorder Treatment Business (2020-2025)

Figure 54. Otsuka Pharmaceutical Revenue Growth Rate in Posterior Segment Eye Disorder Treatment Business (2020-2025)

Figure 55. Santen Revenue Growth Rate in Posterior Segment Eye Disorder Treatment Business (2020-2025)

Figure 56. Lunan Pharma Revenue Growth Rate in Posterior Segment Eye Disorder Treatment Business (2020-2025)

Figure 57. Zizhu Pharma Revenue Growth Rate in Posterior Segment Eye Disorder Treatment Business (2020-2025)

Figure 58. Bayer Revenue Growth Rate in Posterior Segment Eye Disorder Treatment Business (2020-2025)

Figure 59. Roche Revenue Growth Rate in Posterior Segment Eye Disorder Treatment Business (2020-2025)

Figure 60. Alimera Sciences Revenue Growth Rate in Posterior Segment Eye Disorder Treatment Business (2020-2025)

Figure 61. Regeneron Pharmaceuticals Revenue Growth Rate in Posterior Segment Eye Disorder Treatment Business (2020-2025)

Figure 62. Boehringer Ingelheim Revenue Growth Rate in Posterior Segment Eye Disorder Treatment Business (2020-2025)

Figure 63. Kowa Group Revenue Growth Rate in Posterior Segment Eye Disorder Treatment Business (2020-2025)

Figure 64. Ohr Pharmaceutical Revenue Growth Rate in Posterior Segment Eye Disorder Treatment Business (2020-2025)

Figure 65. Quark Pharmaceuticals Revenue Growth Rate in Posterior Segment Eye Disorder Treatment Business (2020-2025)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions